Savara (NASDAQ:SVRA - Get Free Report) had its price objective hoisted by research analysts at JMP Securities from $8.00 to $11.00 in a report released on Thursday,Benzinga reports. The brokerage currently has a "market outperform" rating on the stock. JMP Securities' target price indicates a potential upside of 167.64% from the company's current price.
Several other research analysts have also weighed in on the company. Oppenheimer boosted their price target on Savara from $6.00 to $8.00 and gave the stock an "outperform" rating in a research report on Monday, September 8th. Lifesci Capital raised Savara to a "strong-buy" rating in a report on Tuesday, October 14th. Weiss Ratings reissued a "sell (d-)" rating on shares of Savara in a report on Wednesday, October 8th. HC Wainwright boosted their target price on Savara from $5.00 to $8.00 and gave the stock a "buy" rating in a report on Wednesday, September 3rd. Finally, Guggenheim upped their price objective on Savara from $8.00 to $11.00 and gave the company a "buy" rating in a report on Tuesday, September 9th. One investment analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus target price of $7.83.
Read Our Latest Stock Report on SVRA
Savara Price Performance
Shares of SVRA opened at $4.11 on Thursday. Savara has a 1 year low of $1.89 and a 1 year high of $4.30. The company has a current ratio of 11.08, a quick ratio of 11.08 and a debt-to-equity ratio of 0.25. The stock has a market cap of $710.37 million, a P/E ratio of -8.22 and a beta of 0.46. The stock's 50-day moving average price is $3.48 and its two-hundred day moving average price is $2.91.
Savara (NASDAQ:SVRA - Get Free Report) last released its quarterly earnings data on Wednesday, August 13th. The company reported ($0.14) earnings per share for the quarter, missing the consensus estimate of ($0.12) by ($0.02). On average, equities analysts predict that Savara will post -0.45 earnings per share for the current year.
Hedge Funds Weigh In On Savara
Several large investors have recently bought and sold shares of SVRA. VR Adviser LLC raised its position in Savara by 172.7% in the second quarter. VR Adviser LLC now owns 8,884,263 shares of the company's stock valued at $20,256,000 after purchasing an additional 5,626,624 shares during the last quarter. Bain Capital Life Sciences Investors LLC raised its position in Savara by 20.8% in the first quarter. Bain Capital Life Sciences Investors LLC now owns 17,600,621 shares of the company's stock valued at $48,754,000 after purchasing an additional 3,035,164 shares during the last quarter. Frazier Life Sciences Management L.P. raised its position in Savara by 32.4% in the first quarter. Frazier Life Sciences Management L.P. now owns 11,462,301 shares of the company's stock valued at $31,751,000 after purchasing an additional 2,801,922 shares during the last quarter. Emerald Advisers LLC raised its position in Savara by 32.5% in the first quarter. Emerald Advisers LLC now owns 3,090,213 shares of the company's stock valued at $8,560,000 after purchasing an additional 757,533 shares during the last quarter. Finally, Emerald Mutual Fund Advisers Trust raised its position in Savara by 46.4% in the first quarter. Emerald Mutual Fund Advisers Trust now owns 2,014,456 shares of the company's stock valued at $5,580,000 after purchasing an additional 638,568 shares during the last quarter. 87.93% of the stock is currently owned by institutional investors.
About Savara
(
Get Free Report)
Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Savara, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Savara wasn't on the list.
While Savara currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
